Cost-Benefit Analysis of a Haemophilus Influenzae Type B Meningitis Prevention Programme in The Philippines

Abstract

There would be a positive economic benefit for the Philippine government and for the Filipino society if a Hib vaccination programme was introduced in Manila.

The cost of treatment for child pneumonias and meningitis in the Northern Areas of Pakistan

“…In addition to length of stay, diagnostic procedures, and personnel time also contribute to higher costs. The high cost for hospitalization also argues for the introduction of cost-effective vaccines to prevent the specific agents responsible for causing pneumonia in this area (Levine et al, 1993;Hussey et al, 1995;Miller and McCann, 2000;Limcangco et al, 2001). The cost-effectiveness of Hib immunization programs has been estimated to be $1,448 per life saved in low-income countries.…”

Cost-Benefit Analysis of Haemophilus Influenzae Type B Immunization in Korea

“…The relatively a lower economic efficiency of Hib immunization in Korea resulted mainly from the low incidence rate. Most economic evaluations of Hib immunization showed that the results were very sensitive to the incidence of Hib disease (6, 11, 21, 22). This result differs from those of most other countries (Table 5).…”

“…Therefore, the marginal cost for extending the existing program for DTP and polio immunizations was estimated as an indirect costs of the immunization (6, 9, 11, 21, 22). That is to say, there would be no added cost for an extra visit to the clinic for the Hib vaccine injection.…”

The Use of Cost‐Effectiveness Analysis for Pediatric Immunization in Developing Countries

“…More recently, CEAs have been used to inform potential additions to the core EPI programs to reduce disease burdens particularly significant to developing countries. These include vaccines against Hemophilus influenzae B (Hib) and hepatitis B, widely used in industrialized countries but underutilized in developing countries, and new or potential vaccines against, for example, HIV and dengue fever (Andrus et al 2004; Bos and Postma 2001; Limcangco et al 2001; Shepard et al 2004). Most recently, the introduction of the rotavirus vaccine has been a major confluence of interest for global health researchers, health care providers, and health program funding agencies, due to its promise of reducing a heavy worldwide burden of disease (Walker and Rheingans 2005).…”